Lonza Group AG
LONN
Rang in Aktien
#447
Lonza Group AG, together with its subsidiaries, operates as a contract... Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Aktienkurs
$766.95
Marktkapitalisierung
$53.57B
Veränderung (1 Tag)
1.35%
Veränderung (1 Jahr)
9.01%
Land
CH
Handel Lonza Group AG (LONN)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Lonza Group AG (LONN)
Anzahl der ausstehenden Aktien zum October 2026: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Lonza Group AG beträgt die aktuelle Anzahl der ausstehenden Aktien 0. Am Ende von October 2026 hatte das Unternehmen 0 ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Lonza Group AG (LONN) von 2004 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2025 | 70.02M | -1.68% |
| 2024 | 71.22M | -3.30% |
| 2023 | 73.65M | -0.78% |
| 2022 | 74.23M | -0.04% |
| 2021 | 74.26M | -0.20% |
| 2020 | 74.40M | 0.40% |
| 2019 | 74.11M | -0.40% |
| 2018 | 74.41M | 9.62% |
| 2017 | 67.88M | 28.40% |
| 2016 | 52.87M | 0.39% |
| 2015 | 52.66M | 0.91% |
| 2014 | 52.19M | 0.18% |
| 2013 | 52.10M | -6.80% |
| 2012 | 55.90M | 0.28% |
| 2011 | 55.74M | -1.48% |
| 2010 | 56.58M | 3.22% |
| 2009 | 54.81M | -3.69% |
| 2008 | 56.91M | -0.10% |
| 2007 | 56.97M | -3.42% |
| 2006 | 58.99M | 15.34% |
| 2005 | 51.15M | -0.01% |
| 2004 | 51.15M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| 62.19M | - |
NL
|
|
| 0.00 | - |
BE
|
